---
title: "Directly hitting the afternoon of the first day of the 2025 National Conference: Pfizer, Qilu, and many other Chinese and foreign companies enter the venue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263434524.md"
description: "The negotiation for the National Medical Insurance Catalog in 2025 officially started today. Reporters on-site learned that around 1:30 PM, the participating companies included Boehringer Ingelheim, Pfizer, Qilu Pharmaceutical, Kangyuan Pharmaceutical, Baile Pharmaceutical, Shengdi Pharmaceutical, Fosun Pharma, and Fresenius Kabi, among others. Earlier in the morning, the participating companies included LIVZON PHARMA, Innovent Biologics, Roche, and AstraZeneca"
datetime: "2025-10-30T06:19:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263434524.md)
  - [en](https://longbridge.com/en/news/263434524.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263434524.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/263434524.md) | [繁體中文](https://longbridge.com/zh-HK/news/263434524.md)


# Directly hitting the afternoon of the first day of the 2025 National Conference: Pfizer, Qilu, and many other Chinese and foreign companies enter the venue

The negotiation for the national medical insurance catalog in 2025 officially started today. Journalists on site learned that around 1:30 PM, the participating companies included Boehringer Ingelheim, Pfizer, Qilu Pharmaceutical, Kangyuan Pharmaceutical, Baile Pharmaceutical, Shengdi Pharmaceutical, Fosun Pharma, and Fresenius Kabi, among others. Earlier in the morning, the participating companies included LIVZON PHARMA, Innovent Biologics, Roche, and AstraZeneca

### Related Stocks

- [LIVZON GROUP (000513.CN)](https://longbridge.com/en/quote/000513.CN.md)
- [LIVZON PHARMA (01513.HK)](https://longbridge.com/en/quote/01513.HK.md)
- [Pfizer Inc. (PFE.US)](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis | PFE Stock News](https://longbridge.com/en/news/278375686.md)
- [Pfizer Gains Chinese Approval for GLP-1 Weight Management Drug Enochlutide](https://longbridge.com/en/news/278064724.md)
- [China Clears Weight-Loss Shot As Pfizer Enters Crowded Market](https://longbridge.com/en/news/278109664.md)
- [Pfizer, Other Global Pharma Giants Are Pouring Big Bucks Into Licensing Chinese Weight-Loss Drugs](https://longbridge.com/en/news/276889928.md)
- [BUZZ-Pfizer's new dermatitis drug shows mid-stage success; shares down](https://longbridge.com/en/news/278378691.md)